Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NEOG by emailGet an email when NEOG pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NEOG, unsubscribe in one click. Privacy
📣 What NEOG Says Is Next
fourth quarter · “Company provides FY 2027 financial guidance for revenue and Adjusted EBITDA 1 1 Non-GAAP financial measures; see explanations and reconciliations that follow LANSING, July 30, 2026 – Neogen ® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced its financial results for the fiscal fourth quarter and full fiscal year 2026 and provided financial guidance for its fiscal year first quarter and full fiscal year 2027.”
Company press release, Jul 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NEOG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NEOG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.